AzTrials
AzTrials

Kangaroo Mother CareOMWaNANCT02811432

Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa

A study testing Kangaroo mother care in people with Kangaroo Mother Care and Preterm Infant, run by London School of Hygiene and Tropical Medicine at 4 sites in Uganda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

We will conduct an individually randomised, controlled, superiority trial with two parallel groups; an intervention arm allocated to receive KMC and a control arm receiving 'standard' care. Read more about this study

Who is it for?
Ages 1 hour to 48 hours
What is being tested?
Kangaroo mother care
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,221 participants
Where
4 sitesUganda
Study dates
13 Oct 2019to 30 Sep 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 hour to 48 hours
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Liveborn at Jinja Hospital, Masaka Hospital, Entebbe Hospital, or Iganga Hospital
  • Singleton or twin pregnancy
  • Birthweight ≥700g and ≤2000g
  • Chronological age 1-48 hours at time of screening
  • Alive at time of recruitment
  • Parent/caregiver able and willing to provide KMC
  • Parent/caregiver willing to attend follow-up visit
  • Indication for KMC "uncertain" according to WHO guideline concerning clinical stability: pragmatically defined as receiving ≥1 therapy: oxygen, CPAP, IV fluids, therapeutic antibiotics, phenobarbital

Who cannot join

  • Outborn
  • Result of triplet or higher order multifetal pregnancy
  • Indication for KMC "certain" according to WHO guidelines: pragmatically defined as clinically well neonates receiving none of the above therapy-based criteria
  • Severely life-threatening instability defined as SpO2 <88% in oxygen AND ≥1 of:
  • Respiratory rate <20 or >100 breaths/min
  • Apnoea requiring bag-mask ventilation
Show all 12Show fewer
  • HR <100 or >200 bpm
  • Severe jaundice requiring immediate management
  • Active neonatal seizures
  • Major congenital malformation
  • Parent does not provide written informed consent to participate in trial
  • Mother or neonate enrolled in another MRC/UVRI research project

Trial locations and contacts

4 sites in 1 country.

Uganda4 sites
  • Entebbe

    Entebbe

  • Iganga District Hospital

    Iganga

  • Jinja Regional Referral Hospital

    Jinja

  • Masaka Regional Referral Hospital

    Masaka

Other trials in Uganda

About this study

Official title: The OMWaNA Study: Operationalising Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa: a Multi-site Randomised Controlled Trial to Examine Mortality Impact in Uganda

We will conduct an individually randomised, controlled, superiority trial with two parallel groups; an intervention arm allocated to receive KMC and a control arm receiving 'standard' care. The primary aim is to examine the impact of KMC initiated before stabilisation on mortality within 7 days relative to standard care amongst neonates ≤2000g at four hospitals in Uganda. We hypothesise that neonates in the arm allocated to receive KMC before stabilisation will have a 25% overall reduction in mortality within 7 days compared to neonates allocated to receive standard care.

Read the detailed description

METHODS Study setting, design, and participants The OMWaNA trial was an individually randomised, controlled, superiority trial with two parallel arms allocated in a 1:1 ratio to receive KMC initiated before stabilisation (intervention) or standard care (control). The trial was conducted in the neonatal units (WHO level-2) of five government hospitals in Uganda (appendix p 5). Infrastructure and equipment improvements as well as training were required prior to trial initiation, as described previously.10 All hospitals were provided with essential equipment and supplies to support the provision of KMC and level-2 newborn care. Details regarding study context and methods have been published in the trial protocol9 and are briefly summarised here. Ugandan practice is that maternity and newborn care should be provided free of charge in government health facilities;11 however, families are expected to support caregivers to meet essential needs such as meals.

The trial is reported here in accordance with the CONSORT guidelines. All live-born neonates, aged 1 to <48 hours and weighing 700-2000g, who were admitted to participating hospitals and for whom the indication for KMC was "uncertain" according to WHO guidance concerning clinical stability, defined as receiving ≥1 therapy (oxygen, continuous positive airway pressure [CPAP] where available, intravenous [IV] fluids, therapeutic antibiotics, anti-seizure medication), were eligible for inclusion. Exclusion criteria included triplet or higher multi-fetal pregnancy (unless pregnancy resulted in demise of ≥1 fetus) and parent/caregiver being unable/unwilling to provide either consent, KMC, and/or attend follow-up visits. Neonates with life-threatening instability, severe jaundice requiring immediate management, active seizures, or major congenital malformations were also excluded. The study was approved by the Research Ethics Committees of Uganda Virus Research Institute (GC/127/19/06/717), Uganda National Council of Science and Technology (HS 2645), and London School of Hygiene \& Tropical Medicine (LSHTM, 16972). The trial was overseen by a steering committee and an independent data and safety monitoring board (DSMB).

Screening and informed consent All admitted neonates weighing ≤2000g were screened for eligibility by study staff. Stable neonates (meeting WHO 2019 criteria for KMC eligibility) were excluded and remaining neonates were assessed for eligibility. Those who met criteria for 'life-threatening instability' or who had conditions precluding KMC (e.g., seizures, jaundice), were reassessed every 3 hours up to 48 hours, after which they were excluded. Written informed parental consent was obtained for all participants.

Randomisation, allocation concealment and masking A random allocation sequence was computer-generated using permuted blocks of varying sizes stratified by birthweight (<1000g, 1000-1499g, ≥1500g) and recruitment site. Allocation concealment was done by programming the allocation sequence into the screening database and revealing treatment group only when screening of eligible neonates was complete. Neonates from multiple births (twins or triplets) were allocated to the same arm according to first-born allocation.14 Masking of parents, caregivers, or healthcare workers was not possible due to the nature of the KMC intervention.

Procedures In the intervention arm, KMC was initiated soon after randomisation. Neonates were naked except for hat and diaper, placed prone and skin-to-skin on caregiver's chest, and secured using a KMC wrap. Adjustable beds were provided to facilitate continuous skin-to-skin care. KMC duration was charted by caregivers and verified by study staff. When not in KMC (e.g., during maternal bathing), incubator or radiant heater care was commenced. Study personnel, in addition to hospital staff, provided continuous KMC counselling throughout the hospitalisation. Control arm neonates were cared for in an incubator or radiant heater, as per hospital practice. Caregivers could have physical contact with their newborn but skin-to-skin contact was not initiated until stability criteria were met.9 Once stable, newborns were transferred to routine (intermittent) KMC. Neonates in both arms received standard clinical care according to hospital guidelines.

Being tested
Kangaroo mother care, Standard care
Keywords
Kangaroo mother care, Preterm, Low birthweight, Neonatal, Newborn, Randomised trial
Medical subject headings
Premature Birth, Perinatal Death, Hypothermia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Kangaroo mother careOther

    Also called Skin-to-skin care

    Skin-to-skin care (target: at least 18 hours per day)

  • Standard careOther

    Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC

Study groups in NCT02811432
Study groupRoleWhat they receive
Kangaroo mother careExperimentalSkin-to-skin care initiated as soon as possible following randomisation
Receives: Other: Kangaroo mother care
Standard careActive comparatorIncubator or radiant warmer
Receives: Other: Standard care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mortality Within 7 Days

    early neonatal mortality at 7 days

    Measured: 7 days

Secondary outcomes (10)
  1. Prevalence of Hypothermia at 24 Hours Post-randomisation

    Prevalence of hypothermia at 24 hours post-randomisation using axillary temperature was assessed using a digital thermometer.

    Measured: 24 hours

  2. Time From Intervention/Control Procedures Starting to Clinical Stabilisation

    Time-to-stabilization was defined as the first time at which a neonate had met all of the following criteria for a continuous period of at least 24 hours: breathing spontaneously with SpO2 >90% in room air; no need for supplemental oxygen or CPAP; respiratory rate 40-59 breaths per minute; no apneic episodes; heart rate 80-179 beats per minute; axillary temperature 36.0-37.4 °C; and no need for intravenous fluids.

    Measured: 30 days

  3. Time From Starting Intervention/Control Procedures to Death

    The date and time of death were prospectively recorded from the death certificate for in-hospital deaths. For deaths occurring after discharge, the date was recorded based on parent/caregiver verbal report. Median and IQR of time-to-event calculated as the 50th and 25th to 75th percentile of the distribution of event times among those who experienced the event.

    Measured: 30 days

  4. Mean Duration of Hospital Stay in Days

    The date and time of hospital admission and discharge were documented prospectively for the first admission episode.

    Measured: 30 days

  5. Proportion of Neonates Exclusively Breastmilk Feeding at Discharge

    Proportion of neonates who were exclusively breastmilk feeding at discharge, from the breast or by other means

    Measured: 30 days

  6. Mortality Within 28 Days

    All-cause mortality within 28 days. Vital status was documented at the 28-30-day follow-up visit. If participants did not attend, a telephone call was made the same day to ascertain outcome.

    Measured: 28 days

  7. Frequency of Readmission

    Episodes in which a neonate was readmitted to the index hospital were prospectively recorded. Episodes in which a neonate was readmitted to a different hospital were recorded based on parent/caregiver verbal report.

    Measured: 30 days

  8. Daily Weight Gain at 28 Days

    Mean daily weight gain was calculated as the difference between weight at enrollment and 28-30-day follow-up, as measured by the study scale.

    Measured: 28 days

  9. Infant-caregiver Attachment at 28 Days

    The intention-to-treat analysis assessed the mean difference in Maternal Infant Responsiveness Instrument score between the two arms. Scores range from 0 to 110, with higher scores indicating greater attachment.

    Measured: 28 days

  10. Women's Well-being at 28 Days

    The intention-to-treat analysis assessed the mean difference in Women's Capabilities Index (WCI) score between the two arms. The WCI has a scale of 0 to 1, with higher scores indicating greater wellbeing. The analysis excluded duplicate entries for mothers of enrolled twins/triplets.

    Measured: 28 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jun 2016 (estimated)
  2. Study start13 Oct 2019
  3. Primary completion30 Sep 2022
  4. Study completion30 Sep 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,221 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02811432
Sponsor's protocol ID
0
Acronym
OMWaNA
Status last verified
Sep 2023
First submitted
21 Jun 2016
Last updated
8 Jan 2026
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: LSHTM Data Compass

Publications

  • Medvedev MM, Tumukunde V, Mambule I, Tann CJ, Waiswa P, Canter RR, Hansen CH, Ekirapa-Kiracho E, Katumba K, Pitt C, Greco G, Brotherton H, Elbourne D, Seeley J, Nyirenda M, Allen E, Lawn JE. Operationalising kangaroo Mother care before stabilisation amongst low birth Weight Neonates in Africa (OMWaNA): protocol for a randomised controlled trial to examine mortality impact in Uganda. Trials. 2020 Jan 31;21(1):126. doi: 10.1186/s13063-019-4044-6.

    PubMed 32005286
  • Medvedev MM, Tumukunde V, Kirabo-Nagemi C, Greco G, Mambule I, Katumba K, Waiswa P, Tann CJ, Elbourne D, Allen E, Ekirapa-Kiracho E, Pitt C, Lawn JE. Process and costs for readiness to safely implement immediate kangaroo mother care: a mixed methods evaluation from the OMWaNA trial at five hospitals in Uganda. BMC Health Serv Res. 2023 Jun 10;23(1):613. doi: 10.1186/s12913-023-09624-z.

    PubMed 37301974
  • Tumukunde V, Medvedev MM, Tann CJ, Mambule I, Pitt C, Opondo C, Kakande A, Canter R, Haroon Y, Kirabo-Nagemi C, Abaasa A, Okot W, Katongole F, Ssenyonga R, Niombi N, Nanyunja C, Elbourne D, Greco G, Ekirapa-Kiracho E, Nyirenda M, Allen E, Waiswa P, Lawn JE; OMWaNA Collaborative Authorship Group. Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation. Lancet. 2024 Jun 8;403(10443):2520-2532. doi: 10.1016/S0140-6736(24)00064-3. Epub 2024 May 13.

    PubMed 38754454

Questions about this trial

What is this clinical trial studying?

A study testing Kangaroo mother care in people with Kangaroo Mother Care and Preterm Infant, run by London School of Hygiene and Tropical Medicine at 4 sites in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mortality Within 7 Days (time frame: 7 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02811432, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in